All In Biotech

Drug Trial Radar · NCT07001319

Study of GS-3242 in Participants With HIV-1; Substudy-05

An Umbrella Phase 1b, Open-label, Multi-Cohort Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Novel Antiretrovirals in Participants With HIV-1 Substudy-05: GS-3242

Last checked: Nov 19, 2026Latest source record: May 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

27

Actual

Start

May 29, 2025

Primary completion

Mar 3, 2026

Study completion Apr 16, 2026

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Jun 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is part of a master study. The goal of master protocol (GS-US-544-5905, NCT05585307) is to learn how novel antiretrovirals (medicines that stop the virus from multiplying) affect the human immunodeficiency virus-1 (HIV-1) infection in people living with HIV (PWH). Substudy GS-US-544-5905-05 is to learn more about the study drug GS-3242 in PWH.

Conditions

  • HIV-1-infection

Interventions

  • GS-3242Drug

    Administered orally

  • BVYDrug

    Administered orally

  • Standard of CareDrug

    Antiretroviral therapy, administered orally Non-NNRTIs, examples: ABC/ DTG/3TC; DTG plus (TAF or TDF) plus (FTC or 3TC)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Plasma Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) (log10 Copies/mL) at Day 11 Relative to Historical Placebo DataTime frame: Baseline, Day 11

Locations

28 sites in 3 countries. Site status is shown where the registry gives one.

  • Franco Felizarta, MD

    Bakersfield, California

  • Ruane Clinical Research Group, Inc

    Los Angeles, California

  • Mills Clinical Research

    Los Angeles, California

  • Quest Clinical Research

    San Francisco, California

  • Washington Health Institute

    Washington D.C., District of Columbia

  • Midland Florida Clinical Research Center, LLC

    DeLand, Florida

  • AIDS Healthcare Foundation - Northpoint

    Fort Lauderdale, Florida

  • Midway Immunology & Research Center, LLC

    Ft. Pierce, Florida

  • BLISS Health

    Orlando, Florida

  • Orlando Immunology Center, PA

    Orlando, Florida

  • Triple O Research Institute, P.A.

    West Palm Beach, Florida

  • Chatham County Health Department

    Savannah, Georgia

  • Indiana University School of Medicine

    Indianapolis, Indiana

  • Be Well Medical Center

    Berkley, Michigan

  • KC CARE Health Center

    Kansas City, Missouri

  • University of Cincinnati College of Medicine

    Cincinnati, Ohio

  • Central Texas Clinical Research

    Austin, Texas

  • Prism Health North Texas

    Dallas, Texas

  • North Texas Infectious Diseases Consultant's, P.A.

    Dallas, Texas

  • AXCES Research Group, LLC

    El Paso, Texas

  • AXCES Research Group, LLC

    Salt Lake City, Utah

  • ProcliniQ Investigación Clínica S.A. de C.V

    Mexico City, Mexico

  • Institute of HIV Research and Innovation (IHRI)

    Bangkok, Thailand

  • Faculty of Medicine Ramathibodi Hospital, Mahidol University

    Bangkok, Thailand

  • Faculty of Medicine Siriraj Hospital, Mahidol University

    Bangkok, Thailand

  • Srinagarind Hospital, Faculty of Medicine, Khon Kaen University

    Khon Kaen, Thailand

  • Bamrasnaradura Infectious Diseases Institute

    Nonthaburi, Thailand

  • The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT),Thai Red Cross AIDS and Infectious Disease Research Center

    Pathumwan, Thailand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.